Rapid Nexus Secures First FDA Clearance for Hemastyl Wound-Healing Device

Rapid Nexus, a medical device company, has become the first to receive FDA clearance for an advanced wound-healing gel device designed to support early-stage tissue recovery. The device, Hemastyl, uses a proprietary formulation and applicator system intended for use in emergency medicine, surgery and outpatient wound care. According to the company, Hemastyl can quickly stop bleeding while creating an environment that promotes faster healing and reduces complication risks—key needs in trauma and chronic wound settings.

The clearance arrives as demand grows for technologies that address rising rates of chronic wounds linked to diabetes, vascular diseases and aging populations. Hemastyl’s combined hemostatic and healing-support approach may appeal to emergency departments and ambulatory surgical centers seeking faster, more predictable outcomes.

Posted by MedCloudInsider Editors on 11/17/2025